ReviewFrontiers in neurology
Current status of neural progenitor/stem cells for spinal cord injury: fundamental research and clinical trials.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal cord injury (SCI) causes irreversible neurological deficits and represents a major global health and socioeconomic burden. Although neural progenitor cell (NPC) transplantation is strongly supported by preclinical evidence through cell replacement, intrinsic neuroregeneration, and broad neurotrophic and immunomodulatory effects, its clinical translation has progressed more slowly than anticipated. In parallel, rapid advances in gene editing, biomaterial engineering, and organoid technologies are reshaping the therapeutic landscape. Therefore, it is timely to systematically re-evaluate the current evidence on NPC-based therapies for SCI and to refine future translational strategies. Main body: This review provides an updated and comprehensive overview of NPC therapy for SCI across the full translational continuum. First, we summarize the biological properties, advantages, and limitations of NPCs derived from adult or embryonic neural tissues, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs), highlighting issues such as tumorigenicity, immune responses, and manufacturing standardization. We then focus on efficacy-oriented genetic modifications and engineered delivery systems, including NPCs overexpressing neurotrophic, synaptogenic, or pro-survival factors, as well as combination strategies integrating NPCs with biomaterials, small molecules, or immunomodulatory agents to enhance graft survival, circuit reconstruction, and motor and sensory recovery. Subsequently, we systematically analyze 19 clinical trials of NPC/NSC-based products conducted in 10 countries, covering HuCNS-SC, LCTOPC1, NSI-566, hESC-OPC, and the emerging iPSC-derived product XS228. Trial designs, dosing regimens, routes of administration, safety profiles, and preliminary functional outcomes are compared, and key design principles for next-generation clinical trials and patient selection are proposed. Finally, we discuss organoid-based approaches and artificial intelligence (AI)-assisted decision tools as emerging platforms for disease modeling, protocol optimization, and precision indication refinement. Conclusion: NPC-based therapy for SCI remains at an early but promising translational stage. No NPC product has yet achieved regulatory approval, reflecting persistent challenges in cell source optimization, safety control, graft survival,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.